ArticleDermatology practical & conceptual2026
Topical Metformin Compared with Clobetasol Propionate for Alopecia Areata: Clinical Outcomes from a Comparative Study.
Article in Dermatology practical & conceptual, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAlopecia areata (AA) is alopecia of non-scarring type caused by autoimmune mechanism that affects any area of the body with hair various patterns.
objectivesThe aim of this research was to assess the safety and effectiveness of topical metformin 30% versus clobetasol propionate 0.05% in the treatment of patchy alopecia areata.
methodsThirty-four adult individuals with patchy alopecia areata participated in a randomized clinical trial and were categorized into two groups: Group I (17 participants) with metformin 30% applied twice daily for 12 weeks, and Group II (17 participants), with clobetasol propionate 0.05% administered twice daily for 12 weeks. The 5-point semiquantitative regrowth score (RGS), SALT score, and dermoscopic examination were done to evaluate the therapeutic response.3-12-0
resultsAt week 12, the median hair regrowth score for group I was 2, whereas for the clobetasol propionate group it was 5. There was no difference of significant importance regarding hair regrowth between the two groups, with P=0.133. Significant reductions in SALT score were observed in the two groups, and the reductions were mostly observed in Group II.
conclusionTopical metformin represents a promising and well-tolerated option in alopecia areata treatment. Although the effects of metformin 30% and clobetasol propionate 0.05% were not different, clobetasol was more effective than metformin 30% in treating localized alopecia areata.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.